Damora Therapeutics, Inc.
corporate_fare Company Profile
Damora Therapeutics, Inc. (NASDAQ:DMRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for DMRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for DMRA spans 10-Q, 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- Damora Posts $32M Q3 Loss as R&D Spending Jumps; Cash Runs to 2H 2029
- Damora Q3 Loss Widens to $32.0M; $528.5M Cash Funds Runway Into 2H 2029
- Damora Therapeutics Q2 2026: $31.2M Net Loss, $540.5M Cash, DMR-001 Phase 1/1b Underway
- Damora Launches First Clinical Trial for DMR-001, a Potential Best-in-Class Blood Cancer Therapy
- Damora Therapeutics Extends Cash Runway to 2029 with Strong Q1 Liquidity and Pipeline Progress
Financial Snapshot
Short Interest & Short Volume
10.66 days to coverFINRA reported short interest of 4,689,717 shares in DMRA as of the October 30, 2026 settlement, a 9.0% decrease from the prior period — about 10.7 days to cover at its recent average daily volume. On November 20, 2026, 52.6% of DMRA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for DMRA, detected from its recent SEC filings.
Post-Effective Amendment Filed · ATM Program Update
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →